CANTON, Mass. - Organogenesis Holdings Inc. (NASDAQ: NASDAQ:ORGO), a company specializing in regenerative medicine, has announced a private placement agreement with Avista (NYSE:AVA) Healthcare Partners for the sale of its Series A Convertible Preferred Stock, resulting in $130 million in gross proceeds. The funds, net of commissions and expenses, are earmarked for strategic growth, operational activities, clinical development, and repurchasing shares from certain directors at a price of $3.1597 per share.
The transaction also includes the appointment of Garrett Lustig, a Principal at Avista, to the Organogenesis Board of Directors, effective today. The Preferred Stock is convertible into common stock, with limitations on conversion to maintain investor ownership below 19.99% prior to shareholder approval. The conversion rate is initially set at 263.7358 shares of common stock per $1,000 of liquidation preference, representing a 20% premium over the recent average stock price.
Investors will receive an 8% annual dividend, compounded quarterly, and have redemption rights after seven years. The Preferred Stock will vote alongside common stock within the conversion limits and is entitled to a minimum liquidation preference upon a change of control within the next two years.
The securities issued in this private placement have not been registered under the Securities Act of 1933 and are being sold based on exemptions from registration requirements. The company has agreed to provide registration rights for the Preferred Stock and underlying common stock.
Gary S. Gillheeney, Sr., President, CEO, and Chair of Organogenesis, expressed confidence in the partnership with Avista, highlighting the capital's role in enhancing the company's balance sheet and financial flexibility. Thompson Dean, Chairman of Avista Healthcare Partners, also conveyed strong support for Organogenesis' mission and growth initiatives.
This funding initiative is part of Organogenesis' broader strategy to strengthen its position in advanced wound care and surgical and sports medicine markets. The terms of the transaction can be found in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission. Truist Securities served as the sole placement agent, with Foley Hoag LLP and Ropes & Gray LLP providing legal counsel to Organogenesis and Avista Healthcare Partners, respectively.
This article is based on a press release statement.
InvestingPro Insights
Organogenesis Holdings Inc. (NASDAQ: ORGO) has made a significant move to bolster its financial position with the recent $130 million private placement agreement. This strategic decision aligns with several key metrics and insights from InvestingPro.
According to InvestingPro data, Organogenesis has a market capitalization of $452.74 million, which puts the $130 million capital injection into perspective as a substantial boost to the company's resources. The company's revenue for the last twelve months as of Q2 2024 stands at $448.39 million, with a gross profit margin of 75.14%, indicating a strong ability to generate profit from its sales.
InvestingPro Tips highlight that Organogenesis operates with a moderate level of debt and its liquid assets exceed short-term obligations. These factors suggest that the new capital infusion will further strengthen the company's balance sheet, potentially improving its financial flexibility as mentioned by CEO Gary S. Gillheeney, Sr.
The stock has shown significant momentum recently, with InvestingPro data reporting a 15.13% return over the last week and a 44.63% return over the last three months. This positive trend may reflect investor optimism about the company's growth prospects, which could be further fueled by the strategic use of the new capital for growth initiatives and clinical development.
It's worth noting that while Organogenesis was not profitable over the last twelve months, with a basic EPS of -$0.13, InvestingPro Tips indicate that analysts predict the company will be profitable this year. This projection, combined with the new funding, could signal a turning point for the company's financial performance.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Organogenesis, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.